^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    PRSS1 (Serine Protease 1)

    i
    Other names: PRSS1, Serine Protease 1, Cationic Trypsinogen, Protease, Serine 1, Beta-Trypsin, Trypsin-1, TRYP1, TRP1, TRY1, Nonfunctional Trypsin 1, Digestive Zymogen, TCR V Beta 4.1, Trypsinogen 1, Trypsinogen A, Trypsin I, TRY4
    5d
    PARADISIO 1: French National Cohort of Patients With PRSS1 Mutations (clinicaltrials.gov)
    P=N/A, N=800, Recruiting, Assistance Publique - Hôpitaux de Paris
    New trial
    |
    PRSS1 (Serine Protease 1)
    7d
    Development of a practical GMP-compliant manufacturing process for T cell-derived induced pluripotent stem cells. (PubMed, Cytotherapy)
    In addition to technical validation, we describe a practical approach to optimize the manufacturing workflow to improve operational efficiency within clinical environments. These included predefined process pauses to manage personnel and expiration-prone materials, thereby enhancing the feasibility and reproducibility of iPSC manufacturing in real-world GMP-compliant work environments.
    Journal • IO biomarker
    |
    POU5F1 (POU Class 5 Homeobox 1) • PRSS1 (Serine Protease 1) • FUT4 (Fucosyltransferase 4)
    |
    POU5F1 expression
    |
    OncoPanel™ Assay
    17d
    LEAH: Cohort Evaluation of Body Fluids Early Detection of Cancer in High-risk Individuals (clinicaltrials.gov)
    P=N/A, N=5909, Not yet recruiting, Gustave Roussy, Cancer Campus, Grand Paris | Initiation date: Jun 2025 --> Feb 2026
    Trial initiation date
    |
    TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • STK11 (Serine/threonine kinase 11) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • POLE (DNA Polymerase Epsilon) • RUNX1 (RUNX Family Transcription Factor 1) • BAP1 (BRCA1 Associated Protein 1) • ETV6 (ETS Variant Transcription Factor 6) • MLH1 (MutL homolog 1) • CDK4 (Cyclin-dependent kinase 4) • MSH2 (MutS Homolog 2) • SMAD4 (SMAD family member 4) • CDH1 (Cadherin 1) • SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B) • POLD1 (DNA Polymerase Delta 1) • RAD51C (RAD51 paralog C) • CEBPA (CCAAT Enhancer Binding Protein Alpha) • RAD51D (RAD51 paralog D) • DDX41 (DEAD-Box Helicase 41) • GATA2 (GATA Binding Protein 2) • DICER1 (Dicer 1 Ribonuclease III) • FLCN (Folliculin) • PRSS1 (Serine Protease 1) • SDHD (Succinate Dehydrogenase Complex Subunit D) • TXNIP (Thioredoxin Interacting Protein) • ANKRD26 (Ankyrin Repeat Domain Containing 26) • BMPR1A (Bone Morphogenetic Protein Receptor Type 1A) • HOXB13 (Homeobox B13)
    |
    TP53 mutation • PTEN deletion
    1m
    Using transcriptomics and molecular docking to uncover the pharmacological targets and its associated biological mechanisms of paeoniflorigenone in treating bladder cancer. (PubMed, Discov Oncol)
    It was initially discovered that PAG exerts its therapeutic effects on bladder cancer by targeting multiple pathways and multiple targets. This finding will enhance our comprehension of the potential mechanism by which PAG combats bladder cancer, and it will serve as a theoretical foundation for future research endeavors.
    Journal
    |
    TOP2A (DNA topoisomerase 2-alpha) • TGFBR2 (Transforming Growth Factor Beta Receptor 2) • IL17A (Interleukin 17A) • MMP9 (Matrix metallopeptidase 9) • MMP1 (Matrix metallopeptidase 1) • PRSS1 (Serine Protease 1) • MMP14 (Matrix Metallopeptidase 14) • MMP7 (Matrix metallopeptidase 7)
    2ms
    Pancreatitis in Pediatric Patients with Pancreatic Solid Pseudopapillary Neoplasms: A Single Center Experience. (PubMed, J Pediatr Surg)
    These data represent a unique pediatric patient population requiring coordinated, multi-disciplinary care. Given the identification of either hereditary gene mutations or pancreas divisum in all patients who developed ARP/CP after SPN resection, genetic and anatomic evaluation prior to resection might provide greater understanding of post-operative outcomes after resection. Further evaluation is needed among pediatric patients with SPN.
    Journal
    |
    PRSS1 (Serine Protease 1)
    3ms
    The Role of Alcohol in Pancreatic Diseases: A Comprehensive Perspective. (PubMed, Gastroenterology)
    Although behavioral strategies, such as abstinence, remain essential, pharmacologic and molecularly targeted therapies offer potential complementary approaches. Given the challenges of maintaining sustained abstinence, these adjunctive treatments are critical for slowing or preventing the progression of alcohol-driven pancreatic diseases.
    Review • Journal
    |
    PRSS1 (Serine Protease 1)
    3ms
    TRPV6-related pancreatitis: natural history and the impact of the pancreas-specific deletion on pancreatitis in mice. (PubMed, J Gastroenterol)
    Functionally impaired TRPV6 variants significantly influenced the clinical outcomes of chronic pancreatitis. TRPV6 in pancreatic acinar cells might play a protective role against pancreatitis in mice.
    Preclinical • Journal
    |
    TRPV6 (Transient Receptor Potential Cation Channel Subfamily V Member 6) • PDX1 (Pancreatic And Duodenal Homeobox 1) • PRSS1 (Serine Protease 1) • SPINK1 (Serine peptidase inhibitor, kazal type 1)
    4ms
    Comparison of clinical features and pancreatic cancer risk between genetic mutations associated versus alcohol associated chronic pancreatitis. (PubMed, Pancreatology)
    GCP shows distinct trajectories and an elevated early pancreatic cancer risk, particularly in SPINK1 gene mutation carriers, supporting genotype-stratified surveillance.
    Journal
    |
    PRSS1 (Serine Protease 1) • SPINK1 (Serine peptidase inhibitor, kazal type 1)
    4ms
    Identification of Novel Modifier Genes Associated With Pain in Cystic Fibrosis: An In Silico Gene Discovery. (PubMed, Hum Mutat)
    We identified seven potential pain modifiers in CF, including chymotrypsin C (CTRC), serine protease inhibitor Kazal-Type 1 (SPINK1), tumour necrosis factor (TNF), ATP-binding cassette subfamily B Member 1 (ABCB1), protease serine 1 (PRSS1) and transforming growth factor beta 1 (TGFB1) interacting with the CFTR gene...This in silico analysis highlights potential genes and biochemical pathways implicated in pain pathways that could significantly impact pain perception in people living with CF and their response to prescribed therapies. Further functional analyses are needed to include CF participants and provide a physiological relevance on how genetic polymorphisms of identified GMs may impact their pain phenotype or profile.
    Journal
    |
    ABCB1 (ATP Binding Cassette Subfamily B Member 1) • TGFB1 (Transforming Growth Factor Beta 1) • CFTR (CF Transmembrane Conductance Regulator) • PRSS1 (Serine Protease 1) • SPINK1 (Serine peptidase inhibitor, kazal type 1) • CTRC (Chymotrypsin C)
    4ms
    Diagnosis and treatment strategies for hereditary pancreatic cancer syndrome. (PubMed, Int J Clin Oncol)
    The need for genetic counseling and testing is increasing to support at-risk individuals in making autonomous decisions based on sufficient information. As PC ranks as the second-most common target of CPM in Japan, we must treat these patients and manage at-risk individuals efficiently.
    Review • Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • STK11 (Serine/threonine kinase 11) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • BRCA (Breast cancer early onset) • PRSS1 (Serine Protease 1)
    4ms
    The Cancer of the Pancreas Screening-5 CAPS5)Study (clinicaltrials.gov)
    P3, N=9000, Recruiting, Johns Hopkins University | Trial completion date: Dec 2025 --> Jun 2029 | Trial primary completion date: Oct 2025 --> Dec 2028
    Trial completion date • Trial primary completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MSH2 (MutS Homolog 2) • PRSS1 (Serine Protease 1) • CTRC (Chymotrypsin C)
    |
    PALB2 mutation
    4ms
    A Case of Pancreatic Ductal Adenocarcinoma in PRSS1-Associated Hereditary Pancreatitis in the Absence of High-Grade PanIN: Suggestive of Chromothripsis-Like Tumor Evolution. (PubMed, Pathol Int)
    The background of chronic inflammation, advanced lipomatous atrophy, and environmental exposures may have facilitated this transformation. This case underscores the need to consider alternative, nonlinear pathways of PDAC development in genetically predisposed individuals and highlights the potential utility of molecular surveillance for early detection and risk stratification.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • SMAD4 (SMAD family member 4) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • ATRX (ATRX Chromatin Remodeler) • MSH3 (MutS Homolog 3) • PRSS1 (Serine Protease 1)
    |
    TP53 mutation